Technologies
PDF


WARF: P160186US02

  • Patent applied for.

Efficient In Vitro Assay for Antigen-Specific Tolerance


INVENTORS -

William Burlingham, Dario Vignali

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a T cell-bound cytokine assay for detecting antigen-specific immune suppression in transplant recipients or patients with autoimmune disease.
OVERVIEWThe ultimate goal of organ/tissue transplantation is drug-free acceptance, meaning the recipient’s body is able to tolerate the antigens derived from donor tissue (alloantigens). Unfortunately this scenario is rare, and immunotherapies with powerful side effects must be prescribed to prevent graft rejection.

Research has shown that those patients who are able to tolerate their grafts experience an active suppression of their immune response to specific antigens. The potential to induce such tolerance could help other transplant recipients or patients with autoimmune disorders.

To advance this research, UW–Madison faculty pioneered a method (called the trans vivo DTH bioassay) for measuring antigen-specific regulatory response in vertebrate animals. But there remains a need for a non-animal in vitro method.
THE INVENTIONBuilding on their work, UW–Madison researchers have now developed a T cell-bound cytokine (T-CBC) assay for detecting and quantifying regulatory T cells specific to self-antigens or donor alloantigens. The new method comprises (a) culturing the subject’s T cells for 24 hours in the presence of one or more target antigens and (b) analyzing the cultured T cells for expression of a marker (EBi3; TGFβ/LAP) indicative of antigen-specific immune suppression.
APPLICATIONS
  • In vitro assay for measuring an antigen-specific regulatory response in patients
  • Identifying transplant recipients who are good candidates for cutting back or discontinuing immunosuppression
  • Applications in the cancer space, particularly in the area of DNA vaccines and immunotherapy
KEY BENEFITS
  • Performed on the same 24-hour time scale as the DTH bioassay but requires far fewer cells
  • Avoids the need for vertebrate animals
  • Amenable to automation and miniaturization
  • Supports a variety of applications, including clinical laboratory use
STAGE OF DEVELOPMENTThe researchers have demonstrated the utility of the assay in mouse cells. They have a conducted a preliminary experiment with human cells using human colV-specific regulation of TGFβ-LAP. Surface EBi3 experiments with human cells are in progress. Future direction will focus on miniaturization.
ADDITIONAL INFORMATION
For More Information About the Inventors
Contact Information
For current licensing status, please contact Rafael Diaz at rdiaz@warf.org or (608) 265-9861.
The WARF Advantage

WARF: A Leader in Technology Transfer Since 1925
Since its founding as a private, nonprofit affiliate of the University of Wisconsin–Madison, WARF has provided patent and licensing services to UW–Madison and worked with commercial partners to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.

The University of Wisconsin and WARF –
A Single Location to Accelerate Translational Development of New Drugs

UW–Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities for research in the country, UW–Madison offers state-of-the-art facilities unmatched by most public universities.

These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW–Madison with a complete translational research facility; and the innovative, interdisciplinary Wisconsin Institutes for Discovery, home to the private, nonprofit Morgridge Institute for Research and its public twin, WID, part of the university's graduate school. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.